Form 4: Intellia Director Jesse Goodman Receives Equity Grant

Intellia Therapeutics director Jesse Goodman was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Summary

• Director Jesse Goodman acquired 9,200 restricted stock units (RSUs) of Intellia Therapeutics common stock.
• Director Jesse Goodman was granted stock options to purchase 13,300 shares of common stock at an exercise price of $12.89.
• The transactions occurred on June 9, 2026, as part of standard director compensation.
• Following these transactions, the director's total beneficial ownership of common stock is 33,559 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized vesting schedule for stock options, ensuring long-term commitment.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Market volatility affecting the value of equity-based compensation.
• General risks associated with the biotechnology sector and clinical development timelines.

Future Outlook

The stock options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Management Comments

• The grants represent a contingent right to receive one share of common stock for each restricted stock unit.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology industry to incentivize oversight and long-term strategic alignment.

Comparison to Industry Standards

• Equity compensation for directors at Intellia is consistent with typical practices for mid-cap biotechnology firms.
• The use of both RSUs and stock options is a common retention strategy among peers like CRISPR Therapeutics and Editas Medicine.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of stock options on the earlier of June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Trading, Equity Compensation, Biotech